Ra Pharmaceuticals Inc
(RARX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 264,992 | 292,602 | 173,603 | 191,647 | 209,822 |
| TOTAL | $274,694 | $300,180 | $179,654 | $195,558 | $212,407 |
| Non-Current Assets | |||||
| PPE Net | 4,732 | 4,524 | 4,775 | 5,015 | 5,165 |
| Other Non-Current Assets | 4,726 | 4,234 | 4,809 | 4,496 | 1,648 |
| TOTAL | $9,458 | $8,758 | $9,584 | $9,511 | $6,813 |
| Total Assets | $284,152 | $308,938 | $189,238 | $205,069 | $219,220 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,817 | 327 | 4,498 | 3,364 | 3,245 |
| Accrued Expenses | 15,178 | 10,352 | 6,173 | 5,322 | 6,477 |
| TOTAL | $18,579 | $11,666 | $11,744 | $9,728 | $10,201 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 0 | 0 | 0 | 479 |
| Other Non-Current Liabilities | 3,438 | 3,494 | 3,784 | 4,066 | 0 |
| TOTAL | $3,459 | $3,515 | $3,805 | $4,087 | $1,901 |
| Total Liabilities | $22,038 | $15,181 | $15,549 | $13,815 | $12,102 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 47,329 | 47,143 | 47,015 | 42,303 | 42,189 |
| Common Shares | 47 | 47 | 42 | 42 | 42 |
| Retained earnings | -290,845 | -254,068 | -229,093 | -207,196 | -188,157 |
| TOTAL | $262,114 | $293,757 | $173,689 | $191,254 | $207,118 |
| Total Liabilities And Equity | $284,152 | $308,938 | $189,238 | $205,069 | $219,220 |